A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Inclusion Criteria: * Is diagnosed with CP/CPPS with symptoms for at least 3 months over the last 6 months * Has a NIH-CPSI total score of at least 15 * A score of at least 4 on question 4 (pain) in the NIH-CPSI * Reports pain on palpation of the prostate or the perineum/genital area * Answers "yes" to at least 1 out of 6 items in question 1 and 2 of the NIH-CPSI * Is willing to comply with study requirements such as completing the micturition and symptoms diary and attend all study visits Exclusion Criteria: * Isolated unilateral testicular, penile or scrotal pain as a solitary symptom of pelvic pain * Urinary Tract Infection (UTI) or prostate infection found at screening using the pre- and post massage test or in the last 3 months prior to screening * Any prior prostate and or bladder intervention within 3 months prior to screening * Lower urinary tract malignancy (suspected), such as positive (micro) hematuria in urine sediment or Prostate Specific Antigen (PSA) \>4 ng/mL * Symptomatic urethral stricture or symptomatic bladder or urethral calculi, severe bladder outlet obstruction, overactive bladder with incontinence or Post Void Residual volume, greater than 150 mL * Clinically significant abnormalities on transabdominal ultrasound of bladder and prostate or neurological disease or defect affecting bladder function * Currently active sexually transmittable disease * Substance abuse or any use of delta-9-tetrahydrocannabinol (THC) as assessed by a positive urine test for THC at screening * Major depression, i.e. a Center for Epidemiological Studies Depression Scale score of 27 or more * Any clinically relevant concomitant disease (past or present) which would, in the opinion of the investigator, put the subject at risk or mask measures of efficacy * Use of steroids, immunomodulators, anticonvulsants, cytochrome P4502C8 inhibitors, cannabis/THC based medication, opioid analgetics or antiviral/antimicrobial/antifungal agents during the last 4 weeks before screening * Initiation, discontinuation, or variation in the dose of antidepressants, alpha-blockers, 5-alpha reductase inhibitors, antimuscarinics, benzodiazepines, skeletal muscle relaxants, non-steroidal antiinflammatory drugs, non-opioid analgetics and herbal therapies during the last 4 weeks before screening. Subjects should continue these medications at that same stable dose throughout the study * Clinically relevant abnormal urine or blood safety laboratory values or active hepatic and/or biliary…